Members lead letter to HHS Secretary calling to address current barriers in access for Alzheimer’s diagnostic tests.
FOR IMMEDIATE RELEASE
4 November 2022
Contact: Kevin McGuire, 202-538-2386 (mobile)
WASHINGTON, DC—Today, Representatives Nanette Diaz Barragán (D-CA), Darin LaHood (R-IL), Paul D. Tonko (D-NY), and Fred Upton (R-MI) sent a letter toU.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra and Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure calling for increased access to diagnostic tests able to detect Alzheimer’s disease.
Despite their ability to detect Alzheimer’s disease years and even decades before the onset of symptoms, access to Beta Amyloid Positron Emission Tomography diagnostic testing, known as PET beta amyloid imaging, is significantly limited. Under Medicare, scans are limited to patients enrolled in a clinical trial, and even then patients are limited to one scan in their lifetime. These bureaucratic barriers to access most significantly impact communities of color, rural, and disadvantaged groups.
The members wrote: “There is robust literature demonstrating the importance of early and accurate diagnosis both to Alzheimer’s patients and their caregivers. Consistent and credible evidence accumulated over the past decade demonstrates that PET beta amyloid imaging is a critical step forward in improving the lives of those impacted by this devastating illness. Continuing to force disadvantaged, rural, and minority communities to participate in clinical trials to access important diagnostic tools will only compound existing health disparities in Alzheimer’s disease, continue to limit access for patients, and raise healthcare costs. Millions of Americans and their families are relying on you to improve the quality of their lives in the face of this devastating illness.”
“On behalf of the Alzheimer’s community, thank you to Representatives Tonko, LaHood, Barragán, and Upton for your ongoing bipartisan commitment to the reconsideration process for the current national coverage determination (NCD) for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease. This NCD has significant implications for individuals living with Alzheimer’s. As we enter a time of great progress in Alzheimer’s and dementia research and treatment, we look forward to working with CMS to ensure these individuals are not prohibited from accessing FDA-approved treatments because of outdated restrictions. We remain committed to working with you on this and other critical issues impacting people living with dementia and their families,” said Robert Egge, Alzheimer’s Association chief public policy officer and Alzheimer’s Impact Movement (AIM) executive director.
There is significant evidence showing that access to PET beta amyloid imaging helps patients with Alzheimer’s disease and their care givers develop effective care plans. One study involving more than 11,000 patients showed that 90 days after PET beta amyloid imaging, patient care plans changed for 60.2% of patients initially characterized as having mild cognitive impairment and 63.5% of patients initially characterized as having dementia. With improved access to this important diagnostic tool, more people from low-income communities and communities of color will be able to access their Alzheimer’s diagnosis and treatment options with great assurance, potentially prolonging their lives.
The full text of the letter can be read below and HERE.
October 28, 2022
The Honorable Xavier Becerra
U.S. Department of Health and Human Services
200 Independence Avenue, S.W.
Washington, D.C. 20201
The Honorable Chiquita Brooks-LaSure
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Dear Secretary Becerra and Administrator Brooks-LaSure,
We write to express our strong support of the Center for Medicare and Medicaid Services (CMS)’s reconsideration process for the national coverage determination (NCD) for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (hereafter referred to as “PET beta amyloid imaging”) issued on June 16, 2022. We urge you to not only swiftly reconsider the one scan per patient per lifetime restriction but to also reconsider the coverage with evidence development (CED) for PET beta amyloid imaging (NCD 220.6.20) all together. Further, we request that when CMS re-proposes or revises the NCD, it does not reinforce current barriers in accessing this critical diagnostic tool.
Currently, the coverage with evidence development (CED) framework for this NCD has significantly limited access to this diagnostic tool for Medicare beneficiaries for nearly a decade. There is robust literature demonstrating the importance of early and accurate diagnosis both to Alzheimer’s patients and their caregivers. Consistent and credible evidence accumulated over the past decade demonstrates that PET beta amyloid imaging is a critical step forward in improving the lives of those impacted by this devastating illness.
Since 2013, CMS has worked with a range of stakeholders to generate evidence to demonstrate that these tests should be covered by Medicare. The data generated by the CMS-approved CED trials, as well as outside of those trials, across the Medicare patient population, in clinical settings, and in non-clinical settings is overwhelming. For example, one study involving more than 11,000 patients showed that 90 days after PET beta amyloid imaging, patient care plans changed in 60.2% of patients initially characterized as having mild cognitive impairment and 63.5% of patients initially characterized as having dementia. Hence, imaging was associated with significant alterations in how a patient’s disease was managed. That is in addition to the significant comfort to individuals who learn they do not have Alzheimer’s as a result of diagnostic tools. In that same study, the diagnosis changed from Alzheimer disease to non– Alzheimer disease in 25.1% of patients.
By CMS’ own definition, the intention of CED is to support evidence development for technologies that are “likely to show benefit for the Medicare population, where the available evidence base does not provide a sufficiently persuasive basis for coverage outside the context of a clinical study.” If over the past ten years, CMS has not found a way to generate the evidence necessary to determine that PET beta amyloid imaging should be covered, it calls into question the premise of CED. It also robs individuals with Alzheimer’s, and their loved ones, of the hope for timely access to forthcoming disease-modifying treatments.
Requiring patients to enroll in clinical trials to access PET beta amyloid imaging also contradicts CMS’ stated goal of improving health equity, particularly for patients in rural and urban underserved areas. For example, as CMS is aware, Latino Americans are 1.5 times as likely and Black Americans are twice as likely to develop Alzheimer’s. Despite this, Black participants in Alzheimer’s disease research studies were 35% less likely to be diagnosed with Alzheimer’s and related dementias than white participants.
Additionally, patients in rural communities are more likely to face access challenges to academic medical centers, and other providers offering clinical trials. Continuing to force disadvantaged, rural, and minority communities to participate in clinical trials to access important diagnostic tools will only compound existing health disparities in Alzheimer’s disease, continue to limit access for patients, and raise healthcare costs.
Furthermore, the restriction to one PET scan per patient per lifetime will likely negatively impact participation in trials under CMS’ NCD for monoclonal antibodies (mAB) directed against amyloid for the treatment of Alzheimer’s disease. Due to this restriction, any additional PET scans during the trials will not be covered and those costs will likely fall on the beneficiaries. This unnecessarily raises barriers for low-income beneficiaries and will limit trial participation. It is critical that beneficiaries have access to PET scans so that shared decisions between physicians, patients, and caregivers about whether to initiate this treatment are fully informed. Beneficiaries should not be denied access to innovative therapies because of outdated restrictions on the number of PET scans covered.
Since CMS’ NCD regarding PET beta amyloid imaging was first issued in 2013, evidence demonstrating its clinical utility has grown substantially. Millions of Americans and their families are relying on you to improve the quality of their lives in the face of this devastating illness. With that in mind, and within all relevant rules and regulations, we urge you to swiftly reconsider the NCD for this important diagnostic tool.
|Paul D. Tonko||Darin LaHood|
|Nanette Diaz Barragán||Fred Upton|